Baduanjin on Patients With Schizophrenia
The Feasibility and Efficacy of Baduanjin Exercise on Cognition and Physical Fitness Among Patients With Schizophrenia:Randomized Controlled Trial
1 other identifier
interventional
48
1 country
1
Brief Summary
As an ancient, popular Chinese exercise, Baduanjin is characterized by symmetrical posture, deep breathing and meditation and easy to learn. Previous studies showed immediate effect of Baduanjin on cognition in patients with schizophrenia.The purpose of this study is to investigate the immediate effect and chronic effect of Baduanjin exercise on physical fitness, cognition and daily functions in middle-aged and older adults with schizophrenia.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable schizophrenia
Started Apr 2021
Shorter than P25 for not_applicable schizophrenia
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 3, 2020
CompletedFirst Posted
Study publicly available on registry
June 12, 2020
CompletedStudy Start
First participant enrolled
April 10, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2022
CompletedMay 30, 2025
May 1, 2025
1.2 years
June 3, 2020
May 25, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (6)
Change scores of 6-minute walk test
This test evaluates cardiovascular fitness and walking speed.
Baseline, immediate after treatment, 4-week follow up
Change scores of 30-second chair stand test
This test evaluates muscular endurance of lower-extremities.
Baseline, immediate after treatment, 4-week follow up
Change scores of Timed up-and-go test
This test evaluates functional mobility, agility and balance
Baseline, immediate after treatment, 4-week follow up
Change scores of Montreal cognitive assessment
This test evaluates global cognition.
Baseline, immediate after treatment, 4-week follow up
Change scores of Trail making test (part A and part B)
This test evaluates speed of processing, visual attention and cognitive flexibility.
Baseline, immediate after treatment, 4-week follow up
Change scores of Logical Memory
It is a subtest of the Wechsler Memory Scale. This test evaluates memory.
Baseline, immediate after treatment, 4-week follow up
Secondary Outcomes (3)
Change scores of dual task Timed up-and-go test (manual)
Baseline, immediate after treatment, 4-week follow up
Change scores of dual task Timed up-and-go test (cognitive)
Baseline, immediate after treatment, 4-week follow up
Change scores of Activities of Daily Living Rating Scale III
Baseline, immediate after treatment, 4-week follow up
Study Arms (2)
Baduanjin exercise group
EXPERIMENTALThe intervention group will practice Badunjin in a group which include 6-8 participants and one trained medical staff. The Baduanjin is an ancient Chinese mind-body exercise, which comprised of eight simple movements. The sessions will take place twice a week, 60 minutes per session for a total duration of 12 weeks
Control group
ACTIVE COMPARATORThe control group will receive brisk walking activities. The sessions will take place twice a week, 60 minutes per session for a total duration of 12 weeks
Interventions
The sessions includes 10-minute warm-up, 40-minute Baduanjin exercise and 10-minute cool down.
The sessions includes 10-minute warm-up, 40-minute brisk walking and 10-minute cool down.
Eligibility Criteria
You may qualify if:
- Having a diagnosis of schizophrenia according to the DSM-5.
- Independent adult aged 40 years or older in the day-care center.
- Having a stable mental status without shift in medication and keep in same dose for at least one month.
You may not qualify if:
- Serious physical conditions that will impede participation, such as cardiovascular disease, musculoskeletal disease or pulmonary system disease.
- Visual or auditory impairment that precludes completion of assessment.
- Acute psychosis requiring hospitalization.
- Presence of severe withdrawal or profound cognitive disability that cause difficulties in following instructions.
- Participating in another clinical trial at the same time.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Chang Gung Memorial Hospitallead
- National Taiwan Universitycollaborator
Study Sites (1)
Chang Gung Memorial Hospital, Kaohsiung Medical Center
Kaohsiung City, 833, Taiwan
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 3, 2020
First Posted
June 12, 2020
Study Start
April 10, 2021
Primary Completion
June 30, 2022
Study Completion
June 30, 2022
Last Updated
May 30, 2025
Record last verified: 2025-05